Diagnostic and therapeutic compositions and methods related to G protein-coupled receptor (GPCR) anaphylatoxin C3a receptor
OwnerGlenna C. Burmer, Douglas A. Morningstar +2inventors
InventorsGlenna C. Burmer, Douglas A. Morningstar, Christine L. Roush, Joseph P. Brown
Life of this patent
Estimating the term…
Abstract
Diagnostics, therapeutics and the like based on anaphylatoxin C3a receptor directed against Alzheimer's disease and Parkinson's disease. The compositions and methods and the like can include one or more of peptide, protein, antibody, and nucleic acid components, and can be useful, for example, as agonists, antagonists, probes, antisense and gene therapy compositions and otherwise as may be desired.
Claims13
An assay for the detection of an increased possibility of Alzheimer's disease in a human patient, comprising:
- a) providing a binding partner specific for anaphylatoxin C3a receptor,
- b) contacting the binding partner with at least one of neurons and senile plaques of the patient under conditions suitable and for a time sufficient for the binding partner to bind to anaphylatoxin C3a receptor in the at least one of the neurons and senile plaques,
- c) detecting the binding partner bound to the anaphylatoxin C3a receptor,
- d) determining whether the at least one of the neurons and senile plaques contain altered levels of anaphylatoxin C3a receptor relative to normal and therefrom determining whether the patient has an increased possibility of Alzheimer's disease.
An assay for the detection of an increased possibility of Parkinson's disease in a human patient, comprising:
- a) providing a binding partner specific for anaphylatoxin C3a receptor,
- b) contacting the binding partner with at least one of pigmented or nonpigmented neurons from a substantia nigra of the patient under conditions suitable and for a time sufficient for the binding partner to bind to anaphylatoxin C3a receptor in the at least one of the pigmented or nonpigmented neurons,
- c) detecting the binding partner bound to the anaphylatoxin C3a receptor,
- d) determining whether the at least one of the pigmented or nonpigmented neurons contain decreased levels of anaphylatoxin C3a receptor relative to normal and therefrom determining whether the patient has an increased possibility of Parkinson's disease.
An isolated and purified composition comprising anaphylatoxin C3a receptor and a pharmaceutically acceptable carrier for use in the manufacture of a medicament for inhibiting, preventing or treating at least one of Alzheimer's disease or Parkinson's disease.
A method of manufacturing a medicament able to reduce symptoms associated with Alzheimer's disease or Parkinson's disease in a human patient, comprising combining a pharmaceutically effective amount of an anaphylatoxin C3a receptor agonist, a pharmaceutically acceptable carrier, adjuvant, excipient, buffer and diluent.
A method of manufacturing a medicament able to reduce symptoms associated with Alzheimer's disease or Parkinson's disease in a human patient, comprising combining a pharmaceutically effective amount of an anaphylatoxin C3a receptor antagonist, a pharmaceutically acceptable carrier, adjuvant, excipient, buffer and diluent.
Dependencies are inferred from the claim text.